REDWOOD CITY, Calif., July 17 /PRNewswire-FirstCall/ -- Maxygen, Inc. will host a conference call to discuss the company’s second quarter 2007 financial results at 11:30 a.m. ET (8:30 a.m. PT) on Thursday, August 2, 2007. Russell Howard, Maxygen’s chief executive officer, will host the call. A press release announcing Maxygen’s second quarter 2007 financial results will be issued that same day at approximately 9:00 a.m. ET (6:00 a.m. PT).
The call will include discussion of non-GAAP financial measures. Reconciliation of the non-GAAP financial measures to the most directly applicable GAAP measures can be found at http://www.maxygen.com under the “News” tab.
Participants in the U.S. can access the call by dialing 800.237.9752 and using the passcode 36878670. International participants can dial 617.847.8706 and use the same passcode. A live webcast of the conference call will be available on the Maxygen web site at http://www.maxygen.com/webcasts.
Telephone and webcast replays of the conference call will be available until September 2, 2007. To access the telephone replay, dial 888-286-8010 (U.S.) or 617.801.6888 (international) and use the passcode 31567383. The webcast archive will be available on the Maxygen website at http://www.maxygen.com/webcasts.
About Maxygen
Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs. We look for opportunities where our proprietary protein modification technologies can address significant therapeutic needs. Products developed by Maxygen now in clinical trials include a novel interferon-alpha for the treatment of hepatitis C virus (HCV) infection and a novel G-CSF for the treatment of neutropenia. Maxygen’s approach may allow us to leverage the established development and regulatory paths of approved drugs. We believe this advantage translates to a greater chance of successfully bringing important new drugs to market. http://www.maxygen.com
Maxygen, Inc.
CONTACT: Michele Boudreau, Investor and Public Relations of Maxygen, Inc.,+1-650-279-2088, michele.boudreau@maxygen.com
